Bausch + Lomb Japan Launches Bausch + Lomb AQUALOX® Contact Lenses

First New Innovation in the Bi-weekly Contact Lens Category in Five Years

LAVAL, Quebec, July 6, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc.'s (NYSE: VRX and TSX: VRX) wholly owned subsidiary, Bausch + Lomb, a leading global eye health company, today announced the introduction of Bausch + Lomb AQUALOX(®) contact lenses, the first new innovation in the bi-weekly contact lens category in half a decade, to the Japanese market. The innovative bi-weekly silicone hydrogel lens combines MoistureSeal(®) technology, which helps the lens maintain 95% of its moisture up to a full 16 hours, and provides patients maximum comfort throughout the day.

More than 25 countries, including Canada, France, Germany, Korea, Malaysia and the United States, currently offer Bausch + Lomb AQUALOX contact lenses in the spherical modality (known as Bausch + Lomb ULTRA(® )contact lenses in all countries excluding Japan). In the future, Bausch + Lomb Japan plans to introduce Bausch + Lomb AQUALOX contact lens for Presbyopia to the Japan market followed by the toric version of the lens. (Both are already available in the United States).

"These innovative and unique contact lenses were developed in-house by our scientists and contact lens designers to offer an exceptional lens wearing experience," said Joseph C. Papa, Chairman and CEO of Valeant. "We're pleased to offer this new advanced technology in bi-weekly contact lenses to patients across Japan, a key growth market for the company."

In addition to the Bausch + Lomb AQUALOX lenses, the Bausch + Lomb Japan product portfolio features PureVision(®)2, SofLens(®) 59, and SofLens(®) 38 bi-weekly contact lenses, renu(®) fresh solution, the No. 1 multi-purpose contact lens solution in Japan, as well as the following daily disposable contact lenses, Biotrue(®) ONEday, Biotrue ONEday for Presbyopia, and Medalist(®) ONEday.

About Bausch + Lomb
Bausch + Lomb, a Valeant Pharmaceuticals International, Inc. company, is a leading global eye health organization that is solely focused on protecting, enhancing and restoring people's eyesight. Its core businesses include over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. Bausch + Lomb develops, manufactures and markets one of the most comprehensive product portfolios in our industry, which is available in more than 100 countries.

About Valeant
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. More information about Valeant can be found at

Forward-looking Statements
This press release may contain forward-looking statements which may generally be identified by the use of the words "anticipates", "if approved", "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Company's most recent annual or quarterly report and detailed from time to time in Valeant's other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes, unless required by law.

Contact Information:
Arthur Shannon
877-281-6642 (toll free)

Elif McDonald
877-281-6642 (toll free)

Media Contact:
Lainie Keller

To view the original version on PR Newswire, visit:

SOURCE Valeant Pharmaceuticals International, Inc.